Stock Analiz

Aurinia Pharmaceuticals Inc. (AUPH) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Aurinia Pharmaceuticals’s revenue went from $173000 in fiscal 2016 to $283M in fiscal 2025, growth of about 127.6% a year.

Net income in fiscal 2025 was $287M, a net margin of 101.5%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $322M and net income $314M.

Revenue, profit and cash flow by year

Revenue
2016: $173000162017: $418000172018: $463000182019: $318000192020: $50M202021: $46M212022: $134M222023: $176M232024: $235M242025: $283M25$283M
Net income
2016: -$23M162017: -$71M172018: -$53M182019: -$88M192020: -$103M202021: -$181M212022: -$108M222023: -$78M232024: $6M242025: $287M25$287M
Free cash flow
2016: -$19M20162017: -$41M20172018: -$52M20182019: -$64M20192020: -$72M20202021: -$159M20212022: -$80M20222023: -$33M2023-$33M
EPS (diluted)
2016: $-0.17162017: $-0.53172018: $-0.40182019: $-0.66192020: $-0.77202021: $-1.35212022: $-0.81222023: $-0.58232024: $0.04242025: $2.1425$2.14

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$322M$283M$235M$176M$134M$46M$50M$318000$463000$418000$173000
Gross profit$292M$250M$207M$161M$128M$45M$50M$318000———
Operating income$156M$105M-$5M-$92M-$111M-$181M-$104M-$91M-$55M-$47M-$25M
Net income$314M$287M$6M-$78M-$108M-$181M-$103M-$88M-$53M-$71M-$23M
EPS (diluted)$2.29$2.14$0.04$-0.58$-0.81$-1.35$-0.77$-0.66$-0.40$-0.53$-0.17
R&D$48M$33M$21M$50M$45M$51M$50M$53M$41M——
Revenue growth—+20.4%+34.0%+30.9%+193.9%−9.0%+15660.4%−31.3%+10.8%+141.6%—

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$177M$136M$44M-$33M-$80M-$158M-$70M-$64M-$52M-$41M-$19M
Capital spending-$135000——$0$0-$1M-$2M$0$0-$25000-$15000
Free cash flow$177M——-$33M-$80M-$159M-$72M-$64M-$52M-$41M-$19M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$75M$98M$40M$0$0——————
Stock-based pay$15M$15M$32M$45M$32M$31M$17M$7M$7M$4M$1M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$398M$358M$350M$389M$466M$398M$306M$126M$173M$40M
Debt—$6M$7M$8M$8M$9M$8M—$0$0$0
Equity—$581M$377M$378M$405M$479M$408M$299M$136M$178M$36M
Total assets—$752M$551M$548M$471M$543M$464M$324M$146M$190M$57M
Shares (diluted)135M134M134M134M134M134M134M134M134M134M134M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin90.6%88.5%88.0%91.9%95.8%97.6%100.0%100.0%———
Operating margin48.6%37.1%-2.0%-52.2%-83.2%-396.3%-208.1%-28598.4%-11930.9%-11212.4%-14466.5%
Net margin97.7%101.5%2.5%-44.5%-80.7%-396.8%-204.9%-27794.0%-11464.1%-16935.9%-13465.3%
FCF margin55.0%——-19.1%-59.3%-348.4%-142.7%-19995.3%-11147.1%-9855.0%-10825.4%
ROIC—14.1%-0.9%-18.8%-21.3%-29.3%-25.0%-24.1%-32.1%-26.3%-55.0%
ROE—49.4%1.5%-20.6%-26.7%-37.8%-25.2%-29.6%-39.1%-39.8%-64.8%

Frequently asked questions

What is Aurinia Pharmaceuticals’s annual revenue?

$283M in fiscal 2025 and $322M over the twelve months to September 30, 2026.

How much profit does Aurinia Pharmaceuticals make?

Net income was $287M in fiscal 2025 (net margin 101.5%).

Is Aurinia Pharmaceuticals’s revenue growing?

Yes: revenue rose 20.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.